We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vitrolife AB (VITR) NPV

Sell:163.80 SEK Buy:164.00 SEK Change: 4.30 SEK (2.56%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:163.80 SEK
Buy:164.00 SEK
Change: 4.30 SEK (2.56%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:163.80 SEK
Buy:164.00 SEK
Change: 4.30 SEK (2.56%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

Contact details

Address:
Gustaf Werners gata 2, Vastra Frolunda
GOETEBORG
421 32
Sweden
Telephone:
+46 (31) 7218000
Website:
https://www.vitrolife.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VITR
ISIN:
SE0011205202
Market cap:
22.76 billion SEK
Shares in issue:
135.39 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Jon Sigurdsson
    Chairman of the Board
  • Bronwyn Brophy
    President, Chief Executive Officer
  • Patrik Tolf
    Chief Financial Officer
  • Olivia Natens
    Senior Vice President - Sales and Marketing
  • Frank Pettersson
    Senior Vice President - Human Resources and Sustainability
  • Claus Bisgaard
    Senior Vice President - Technologies
  • Ricardo Capella
    Senior Vice President - Genetic Services
  • Rickard Ericsson
    Senior Vice President - Consumables
  • Guillermo Ferrando
    Vice President - Strategy and Corporate Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.